Home » Newsletters » BioWorld Science

BioWorld Science

March 2, 2022

View Archived Issues

New HDAC6 inhibitors identified at Italfarmaco

Antengene Discover, Shanghai Antengene present new serine/threonine-protein kinase ATR inhibitors

Spexis, University of Zurich describe new antimicrobial peptidomimetics

Complement factor B inhibitors discovered at Shanghai Meiyue Biotech Development

Bayer, Deutsches Krebsforschungszentrum patent aryl hydrocarbon receptor antagonists

SIGLEC-6 targeting inhibits human mast cell degranulation and anaphylaxis

HLA-DPB1*05:01 allele predicts nonresponse to SLIT in allergic rhinitis

JAK1 activation of sensory neurons suppresses lung inflammation

Quanterix collaborates with Lilly on diagnosis and treatment of Alzheimer's disease

LIGHT mediates esophageal remodeling in murine model of eosinophilic esophagitis

HuR ablation ameliorates allergen-induced asthmatic symptoms

Neuropathy may unify disparate long COVID symptoms

Targeting PD-1/PD-L1 pathway prevents allergic immune response

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
Rare earth: Biomarin to use global reach post-$4.8B Amicus buy
BioWorld
Biomarin Pharmaceutical Inc. followed up its May takeover of Inozyme Pharma Inc. with a much larger agreement to acquire Amicus Therapeutics Inc. for $14.50 per...
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...